References
- Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, . Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999;341:394–402.
- Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, . Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484–94.
- Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, September 14, 2011. National Institutes of Health, AIDSinfo; 2011 pp 1–216. Available at: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf (Accessed 28 December 2011).
- de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, . British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008;9:452–502.
- Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol 2001;25:120–3.
- Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44:989–1008.
- Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008;66:179–95.
- Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, . Reduced lopinavir exposure during pregnancy. AIDS 2006;20:1931–9.
- Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, . Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 2010;11:232–8.
- Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007;21: 643–5.
- Dickinson L, Boffito M, Back D, Else L, von Hentig N, Davies G, . Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. Antimicrob Agents Chemother 2011;55:2775–82.
- Dickinson L, Robinson L, Tjia J, Khoo S, Back D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;829:82–90.
- La Porte CJ, Back DJ, Blaschke T. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006;3:4–14.
- Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, . Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther 2008;13:901–7.
- Wolfe R, Carlin JB. Sample-size calculation for a log-transformed outcome measure. Control Clin Trials 1999;20:547–54.
- Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, . Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008;49:485–91.
- Khuong-Josses MA, Azerad D, Boussairi A, Ekoukou D. Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women. HIV Clin Trials 2007;8:254–5.
- Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, . The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007;44:401–10.
- Lambert JS, Else LJ, Jackson V, Breiden J, Gibbons S, Dickinson L, . Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med 2011;12:166–73.
- Ramautarsing RA, van der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, . Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS 2011;25: 1299–303.
- Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, . Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010;24:2193–200.
- Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, . Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010;54:381–8.